CA-CEPTON-TECHNOLOGIES
12.1.2021 12:02:29 CET | Business Wire | Press release
Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, has announced its path-breaking miniature lidar sensor – the Nova - priced at less than $100 for high volume automotive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005035/en/
The Nova is a wide angle near-range lidar sensor intended to address major gaps in proximity detection of objects with current sensor technologies. Featuring best-in-class, high resolution 3D imaging with a high field of view (FOV) of 90-120° (H) and 60-90° (V), depending on configuration, Nova sets a worldwide benchmark with its unprecedented combination of compactness, FOV coverage and affordability.
Powered by Cepton’s patented and proven Micro Motion Technology (MMT® ), the non-rotational, mirrorless, and frictionless Nova lidar can be hidden all around a vehicle to provide a complete 360° view of its immediate surroundings. With a lidar target size of 3.5 cm (W) x 3.5 cm (H) x 7.5 cm (D), and weighing less than 350 g, the ultra-small Nova is an easily embeddable lidar sensor that not only enables optimal styling choices but demonstrates the scalability of MMT® to the smallest form factors.
Nova has an angular resolution of up to 0.3°, with a maximum range of up to 30 m and is therefore ideal for automotive Advanced Driver Assistance Systems (ADAS) and autonomous vehicle (AV) applications such as blind spot detection, small object detection, automated park assist and free space estimation around the vehicle. For vehicles, a multi-lidar architecture can be facilitated, thereby creating a virtual safety zone all around while minimizing disruption to vehicle design aesthetics.
Nova is ideally suited for accurate detection of objects in proximity, such as small children, on-road objects, road edges, stationary objects and more. With this level of capability and its ultra-compact design, Nova can not only support ADAS and AV applications but also autonomous ground vehicle (AGV) and smart industrial applications.
With lidar’s increasing presence in cars and trucks, Cepton has been innovating its technology to meet the stringent requirements from OEMs and Tier 1s while striving to advance lidar designs that enable easy integration in the next generation of automobiles. Nova is the latest representation of Cepton’s state-of-the-art lidar innovation, that encompasses the goal of automotive-grade reliability, low power (<3.5 W) and high performance, along with an elegant, minimalistic design that requires only small amounts of real estate in the vehicle body.
Nova’s modular design and easily accessible components make it highly manufacturable, with very low cost at high volume. Previously, Cepton was one of the first in the industry to announce a <$1,000 volume lidar price for high performance, long range lidar (Vista-X90). Consistent with that trend, Nova is the first high field of view, near-range lidar with a <$100 price point for high automotive volumes. This fulfils Cepton’s objective to bring to market scalable, mass-market lidar solutions that enable the automotive industry to substantially accelerate safety and autonomy innovations in the next generation of vehicles.
“The Nova is an industry-first, transformational lidar that fundamentally changes the game for near-field sensing,” said Cepton CEO Dr. Jun Pei. “Currently, consumer vehicles have been limited to technologies that cannot facilitate true Level 3 or Level 4 autonomy for the mass market. Radars, cameras and ultrasonic sensors suffer from high false positives and false negatives. Rotational lidars are not embeddable, making them impractical for consumer vehicles. Near-range flash lidars either lack the wide field of view or cannot match the power and size requirements to be discretely hidden all around the vehicle. The Nova represents path-breaking lidar innovation for the automotive industry in that it achieves a level of performance that is unmatched for such a small form factor.”
Nova is targeted for high volume production starting in 2023. Due to anticipated high demand for samples, Nova will only be available to select customers in 2021 through Cepton’s Early Access Program . If you would like to be part of this program or would like more details, please contact Mitch Hourtienne, Cepton Senior Director of Business Development at mitch.hourtienne@cepton.com .
To learn more about the Nova and Cepton’s automotive grade lidar capabilities, join Cepton at the upcoming digital CES 2021, from January 11th to 14th , via our virtual booth page (CES registration required). On Jan 12th , Cepton CMO, Dr. T. R. Ramachandran will join North American Lighting (NAL) for a virtual panel discussion on “Impact of Sensors on Mobility ” at 11 a.m. (PST) and present at an online NAL-hosted webinar “Lidar, What’s the Future? ” at 2 p.m. (PST). Watch the online sessions for free to learn more about how lidar is transforming the world and how Cepton’s smart lidar solutions are ideally suited for automotive and smart infrastructure applications.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT® -based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom